 |
Vol.63 No.1 contents | Japanese/English |
 | Full Text of PDF (1723K) Article in Japanese |
- Case Report -
A Case of Small Cell Lung Cancer with COVID-19 Pneumonia During Chemoimmunotherapy
Jun Yano1, Yusuke Takayama1, Ren Seike1, Shohei Mishima1, Hiroyasu Shoda11Department of Respiratory Medicine, Hiroshima City Hiroshima Citizens Hospital, Japan
Background. Many patients have contracted coronavirus infectious disease, emerged in 2019 (COVID-19) during lung cancer treatment. However, few reports of COVID-19 infection occurring during chemoimmunotherapy have been published. Case. The patient was a 50-year-old man with advanced small cell lung cancer who was undergoing chemoimmunotherapy. He presented with fever, anorexia, and contracted COVID-19, which led to pneumonia. Patients with lung cancer may be at increased risk for COVID-19 infection, which could worsen their prognosis. However, the patient's COVID-19 pneumonia improved with dexamethasone, and he was able to resume lung cancer treatment. Conclusion. Chemoimmunotherapy may lead to the development of severe disease in patients with COVID-19. COVID-19 pneumonia is often difficult to differentiate from lung injury caused by immune-related adverse events associated with chemoimmunotherapy. Upon the development of pneumonia, we should always suspect COVID-19, diagnose it early, and treat it appropriately. Furthermore, we need to carefully consider the resumption of lung cancer treatment after COVID-19, depending on the severity of residual fibrosis.
key words: Immune checkpoint inhibitor: ICI, Chemoimmunotherapy, Coronavirus infectious disease, emerged in 2019: COVID-19, Small cell lung cancer
Received: May 24, 2022
Accepted: September 2, 2022
JJLC 63 (1): 27-32, 2023
